News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Drugs & Diseases > Medscape > Trending Clinical Topics

      Top 10 Trends in Medicine, September 2014

      Ryan Syrek

      Disclosures

      September 23, 2014

      #5 Clinical Trend: Pembrolizumab

      Recently approved by the US Food and Drug Administration (FDA), pembrolizumab is the first immunomodulator that acts as a programmed death inhibitor. It has been approved for use in patients with advanced or unresectable melanoma who are not responding to other medications.

      For more in-depth clinical information, see Pembrolizumab.

      Comments

      3090D553-9492-4563-8681-AD288FA52ACE
      Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

      processing....

      Feedback
      Help us make reference on Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this article more useful to clinicians.
      Pleasedo not use this form to submit personal or patient medical information or to report adverse drug events. You are encouraged to report adverse drug event information to the FDA.
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.